Helen Kim - Assembly Biosciences Independent Director
ASMB Stock | USD 13.30 0.08 0.60% |
Director
Ms. Helen S. Kim is an Independent Director of Assembly Biosciences Inc. Ms. Kim joined our Board in March 2018. From November 2014 until January 2018, Ms. Kim served as executive vice president of business development at Kite Pharma, Inc. where she led all business and corporate development initiatives including its sale to Gilead in September 2017. From January 2012 to January 2014, Ms. Kim served as strategic advisor to NGM Biopharmaceuticals, Inc. and from August 2009 to January 2012, Ms. Kim served as chief business officer of NGM Biopharmaceuticals, Inc. Ms. Kims additional industry experience includes executive positions at Kosan Biosciences, Affymax, Inc., Onyx Pharmaceuticals, Inc., Protein Design Labs, Inc. and Chiron Corporationrationration. In addition to her industry experience, from August 2003 to November 2007, Ms. Kim served as chief program officer for the Gordon and Betty Moore Foundation. Currently, she serves as a director on the board of Exicure, Inc., a public company, and Peloton Therapeutics, Inc. Ms. Kim formerly served as a director and member of the audit committee of Sunesis Pharmaceuticals, Inc. and WCCT Global, Inc. and a director of Foresight Labs, VISION 4 since 2018.
Age | 54 |
Tenure | 6 years |
Professional Marks | MBA |
Address | 331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
Phone | 833 509 4583 |
Web | https://www.assemblybio.com |
Assembly Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.5471) % which means that it has lost $0.5471 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0084) %, meaning that it created substantial loss on money invested by shareholders. Assembly Biosciences' management efficiency ratios could be used to measure how well Assembly Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to -1.2. In addition to that, Return On Assets is expected to decline to -0.85. At present, Assembly Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 5.3 M, whereas Non Current Assets Total are forecasted to decline to about 5.3 M.Similar Executives
Showing other executives | DIRECTOR Age | ||
Kimberly Alexy | Western Digital | 47 | |
Matthew Massengill | Western Digital | 55 | |
William Luden | Aris Water Solutions | 73 | |
David Peters | Antero Midstream Partners | 57 | |
Christopher Manning | Antero Midstream Partners | 48 | |
Susan Bostrom | ServiceNow | 60 | |
William Mortimore | Aris Water Solutions | 70 | |
Paula Price | Western Digital | 55 | |
Richard Connor | Antero Midstream Partners | 67 | |
Kathleen Cote | Western Digital | 69 | |
P Poseidon | Aris Water Solutions | 60 | |
Jeffrey Miller | ServiceNow | 68 | |
Len Lauer | Western Digital | 59 | |
Charles Giancarlo | ServiceNow | 58 | |
Margaret Gentle | Cheniere Energy Partners | 40 | |
Vincent Pagano | Cheniere Energy Partners | 68 | |
Martin Cole | Western Digital | 61 | |
Jonathan Chadwick | ServiceNow | 54 | |
Peter Kagan | Antero Midstream Partners | 49 | |
Paul Korus | Antero Midstream Partners | 60 | |
Riekert | Aris Water Solutions | N/A |
Management Performance
Return On Equity | -1.01 | ||||
Return On Asset | -0.55 |
Assembly Biosciences Leadership Team
Elected by the shareholders, the Assembly Biosciences' board of directors comprises two types of representatives: Assembly Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Assembly. The board's role is to monitor Assembly Biosciences' management team and ensure that shareholders' interests are well served. Assembly Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Assembly Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Nicole White, Chief Officer | ||
John McHutchison, President CEO, Director | ||
Adam Zlotnick, Chief CoFounder | ||
Uri Lopatin, Vice President - Research & Development, Chief Medical Officer | ||
Helen Kim, Independent Director | ||
Myron Holubiak, Independent Director | ||
Anthony Altig, Independent Director | ||
Richard Colonno, Chief Scientific Officer | ||
Thomas Rollins, Chief Development Officer | ||
Shannon Ryan, Corporate Relations | ||
Anuj MD, Chief Officer | ||
David Houck, Senior Vice President - Product Development and Portfolio Management | ||
AO FRACP, CEO Director | ||
Jason Okazaki, President CEO | ||
Uri MD, CoFounder Advisor | ||
Michele Anderson, Chief Officer | ||
Dr IV, Chief Officer | ||
Lee Arnold, Chief Scientific Officer | ||
Jacqueline Papkoff, Senior Vice President Chief Scientific Officer Microbiome | ||
Graham Cooper, CFO, COO and Principal Financial Officer and Principal Accounting Officer | ||
Jeanette Bjorkquist, Executive Treasury | ||
William Ringo, Non-Executive Chairman of the Board | ||
Susan Mahony, Director | ||
Richard DiMarchi, Director | ||
Miguel Barbosa, Chief Scientific Officer, Head of Microbiome Program | ||
Steven Knox, Senior Vice President - Clinical Development | ||
Tharaknath Rao, Head VP | ||
Mark Auerbach, Independent Director | ||
MHROD SHRMSCP, Chief Officer | ||
Derek Small, Co-Founder, CEO and President and Director | ||
Alan Lewis, Director | ||
David Barrett, CFO, COO |
Assembly Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Assembly Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -1.01 | ||||
Return On Asset | -0.55 | ||||
Current Valuation | 26.31 M | ||||
Shares Outstanding | 5.48 M | ||||
Shares Owned By Insiders | 32.99 % | ||||
Shares Owned By Institutions | 13.22 % | ||||
Number Of Shares Shorted | 60.23 K | ||||
Price To Earning | (10.58) X | ||||
Price To Book | 1.72 X | ||||
Price To Sales | 3.96 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Assembly Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Assembly Biosciences' short interest history, or implied volatility extrapolated from Assembly Biosciences options trading.
Pair Trading with Assembly Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Assembly Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Assembly Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Assembly Stock
0.75 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against Assembly Stock
0.86 | MEIP | MEI Pharma Financial Report 9th of May 2024 | PairCorr |
0.86 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
0.82 | KA | Kineta Inc Report 29th of March 2024 | PairCorr |
0.72 | CALT | Calliditas Therapeutics Financial Report 21st of May 2024 | PairCorr |
0.7 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Assembly Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Assembly Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Assembly Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Assembly Biosciences to buy it.
The correlation of Assembly Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Assembly Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Assembly Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Assembly Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Assembly Stock analysis
When running Assembly Biosciences' price analysis, check to measure Assembly Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assembly Biosciences is operating at the current time. Most of Assembly Biosciences' value examination focuses on studying past and present price action to predict the probability of Assembly Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assembly Biosciences' price. Additionally, you may evaluate how the addition of Assembly Biosciences to your portfolios can decrease your overall portfolio volatility.
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Transaction History View history of all your transactions and understand their impact on performance | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Assembly Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (17.16) | Quarterly Revenue Growth (1.00) | Return On Assets (0.55) | Return On Equity (1.01) |
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.